Evolent Health (EVH) to Release Quarterly Earnings on Thursday

Evolent Health (NYSE:EVH) is expected to be announcing its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of $0.08 per share and revenue of $460.15 million for the quarter. Evolent Health has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Stock Down 1.7 %

Evolent Health stock opened at $10.51 on Tuesday. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 1-year low of $8.35 and a 1-year high of $33.63. The company has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $11.83. The company has a market cap of $1.22 billion, a P/E ratio of -12.81 and a beta of 1.20.

Insider Buying and Selling at Evolent Health

In other news, Director Diane Holder bought 2,735 shares of the stock in a transaction dated Thursday, March 6th. The shares were bought at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the purchase, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. This trade represents a 4.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley purchased 55,225 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average cost of $9.01 per share, with a total value of $497,577.25. Following the completion of the acquisition, the chief executive officer now owns 762,217 shares in the company, valued at $6,867,575.17. The trade was a 7.81 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,000 shares of company stock valued at $666,315 in the last three months. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolent Health

A hedge fund recently bought a new stake in Evolent Health stock. Brighton Jones LLC bought a new position in shares of Evolent Health, Inc. (NYSE:EVH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 349,109 shares of the technology company’s stock, valued at approximately $3,927,000. Brighton Jones LLC owned approximately 0.30% of Evolent Health as of its most recent SEC filing.

Analysts Set New Price Targets

EVH has been the subject of several analyst reports. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective (down previously from $17.00) on shares of Evolent Health in a report on Friday, February 21st. Canaccord Genuity Group decreased their price target on Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Evolent Health in a research note on Friday, February 21st. JMP Securities reissued a “market outperform” rating and issued a $13.00 target price on shares of Evolent Health in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Monday, March 10th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.